Optimum modality for photodynamic therapy of tumors: Gels containing liposomes with hydrophobic photosensitizers

Drug Development Research

Volumn 68, Issue 5, 2007, Pages 235-252

  Nekvasil, Miloš ^a   Zadinová, Marie ^b   Tahotná, Ludmila ^a   Žáčková, Markéta ^a   Poučková, Pavla ^b   Ježek, Petr ^a  

^a INSTITUTE OF PHYSIOLOGY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Hydroxy aluminum phthalocyanine; Liposomal photosensitizer gels; Meso tetrakisphenylporphyrin; Microfluidization; Photodynamic therapy of tumors

Indexed keywords

ANTINEOPLASTIC AGENT; BROMOPYRUVIC ACID; CISPLATIN; HYDROXY ALUMINUM PHTHALOCYANINE; LIPOSOME; MESO TETRAKISPHENYLPORPHYRIN; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG;

AMELANOTIC MELANOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL CELL CARCINOMA; BREAST CARCINOMA; CANCER REGRESSION; CIRCULATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DEVICE; DRUG ABSORPTION; DRUG FORMULATION; FEMALE; FILTER; GEL; HISTOLOGY; HUMAN; HUMAN CELL; MICROFLUIDIZER; MOUSE; NONHUMAN; ORGAN; PHOTODYNAMIC THERAPY; TUMOR; TUMOR CELL; TUMOR NECROSIS;

EID: 36849090531     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20184     Document Type: Article

References (46)

1. Alexandratou E, Yova D, Loupas S. 2005. A confocal microscopy study of the very early cellular response to oxidative stress induced by zinc phthalocyanine sensitization. Free Radic Biol Med 39:1119-1127.
2. Allen CM, Langlois R, Sharman WM, La Madeleine C, Van Lier JE. 2002. Photodynamic properties of amphiphilic derivatives of aluminum tetrasulfophthalocyanine. Photochem Photobiol 76: 208-216.
3. Allison RR, Bagnato VS, Cuenca RE, Downie GH, Sibata CH. 2006a. The future of photodynamic therapy in oncology. Future Oncol 2:53-71.
4. Allison RR, Sibata CH, Downie GH, Cuenca RE. 2006b. Photodynamic therapy of the intact breast. Photodiagn Photodynam Ther 3:139-146.
5. Almeida RD, Manadas BJ, Carvalho AP, Duarte CB. 2004. Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta 1704:59-86.
6. Boyle RW, Paquette B, van Lier JE. 1992. Biological activities of phthalocyanines. XIV. Effect of hydrophobic phthalimidomethyl groups on the in vivo phototoxicity and mechanism of photodynamic action of sulphonated aluminum phthalocyanines. Br J Cancer 65:813-817.
7. Boyle RW, Dolphin D. 1996. Structure and biodistribution relationships of photodynamic sensitizers. Photochem Photobiol 64: 469-485.
8. Brown SB, Brown EA, Walker I. 2004. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 5: 497-507.
9. Canete M, Villanueva A, Domínguez V, Polo S, Juarranz A, Stockert JC. 1998. meso-tetraphenylporphyrin: photosensitizing properties and cytotoxic effects on cultured tumor cells. Int J Oncol 13: 497-504.
10. Cuomo V, Jori G, Rihter B, Kenney ME, Rodgers MAJ. 1990. Liposome/delivered Si(IV)/naphthalocyanine as a photodynamic sensitise for experimental tumors: pharmacokinetic and phototherapeutic studies. Br J Cancer 62:966-970.
11. Derycke ASL, de Witte PAM. 2004. Liposomes for photodynamic therapy. Adv Drug Deliv Rev 56:17-30.
12. Detty MR, Gibson SL, Wagner SJ. 2004. Current clinical and preclinical photosensitizers for use in photodynamic therapy. J Med Chem 47:3897-3915.
13. Dolmans DEJGJ, Fukumura D, Jain RK. 2003. Photodynamic therapy for cancer. Nat Rev Cancer 3:380-387.
14. Fabris C, Soncin M, Miotto G, Fantetti L, Chitti G, Dei D, Roncucci G, Jori G. 2006. Zn(II)-phthalocyanines as phototherapeutic agents for cutaneous diseases. Photosensitization of fibroblasts and keratinocytes. J Photochem Photobiol B Biol 83: 48-54.
15. Fingar VH, Wieman TJ, Doak KW. 1991. Mechanistic studies of PDT-induced vascular damage: evidence that eicosanoids mediate this process. Int J Radiat Biol 60:303-309.
16. Hornung R. 2001. Photomedical approaches for the diagnosis and treatment of gynaecologic cancers. Curr Drug Targets Immune Endocr Metabol Disord 1:165-177.
17. Inaba M, Tazuko T, Fujimoto S, Sakurai MK, Ohnishi Y, Ueyama Y, Nomura T. 1986. Evaluation of response rates to various antitumor agents of human gastric tumors implanted in nude mice. Jap J Cancer Res 77:190-196.
18. Ježek P, Hlavatá L. 2005. Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and organism. Int J Biochem Cell Biol 37:2478-2503.
19. Ježek P, Nekvasil M, škobisová E, Urbánková E, Jirsa M, Zadinová M, Poučková P, Klepáček I. 2003. Experimental photodynamic therapy with meso-tetrakisphenylporphyrin (TPP) in liposomes leads to disintegration of human amelanotic melanoma implanted to nude mice. Int J Cancer 103:693-702.
20. Jirsa M Jr, Poučková P, Doležal J, Pospíšil J, Jirsa M. 1991. Hyperbaric oxygen and photodynamic therapy in tumor-bearing nude mice. Eur J Cancer 27:109.
21. Kepczynski M, Nawalny K, Jachimska B, Romek M, Nowakowska M. 2006. Pegylated tetraarylporphyrin entrapped in liposomal membranes. A possible novel drug-carrier system for photodynamic therapy. Colloids Surfaces B: Biointerfaces 49:22-30.
22. Konan YN, Gurny R, Allemann E. 2002. State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B Biol 66:89-106.
23. Kormeili T, Yamauchi PS, Lowe NJ. 2004. Topical photodynamic therapy in clinical dermatology. Br J Dermatol 150:1061-1069.
24. Lapeš M, Petera J, Jirsa M. 1996. Photodynamic therapy of cutaneous metastases of breast cancer after local application of meso-tetra-(para-sulfophenyl)-porphine (TPPS4). J Photochem Photobiol B Biol 36:205-207.
25. Lovčinský M, Borecký J, Kubát P, Ježek P. 1999. meso-tetraphenylporphyrin in liposomes as a suitable photosensitizer for photodynamic therapy of tumors. Gen Physiol Biophys 18:107-118.
26. Love WG, Duk S, Biolo R, Jori G, Taylor PW. 1996. Liposome-mediated delivery of photosensitizers: localization of zinc (II)-phthalocyamne within implanted tumors after intravenous administration. Photochem Photobiol 63:656-661.
27. MacDonald RC, MacDonald RI, Menco BP, Takeshita K, Subbarao NK, Hu LR. 1991. Small-volume extrusion apparatus for preparation of large unilamellar vesicles. Biochim Biophys Acta 1061: 297-303.
28. Margarone P, Gregoire M-J, Scasnárt V, Ali H, van Lier JE. 1996. Structure-photodynamic relationships of a series of 4-substituted zinc phthalocyanines. Photochem Photobiol 63:217-223.
29. Moša M, Zitko M, Poučková P. 1997. Distribution and photodynamic effect of zinc phthalocyanine disulfonate in nude mice bearing mammary carcinoma. Neoplasma 44:178-183.
30. Nepomuceno MF, Tabak M, Vercesi AE. 2002. Opposite effects of Mn(III) and Fe(III) forms of meso-tetrakis(4-N-methylpyridiniumyl)porphyrins on isolated rat liver mitochondria. J Bioenerg Biomembr 34:41-47.
31. Nonaka M, Ikeda H, Inokuchi T. 2002. Effect of combined photodynamic and chemotherapeutic treatment on lymphoma cells in vitro. Cancer Lett 184:171-178.
32. Nyman ES, Hynninen PH. 2004. Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy. J Photochem Photobiol B Biol 73:1-28.
33. Oleinick NL, Morris RL, Belichenko I. 2002. The role of apoptosis in response to photodynamic therapy: what where, why and how. Photochem Photobiol Sci 1:1-21.
34. Osaki T, Takagi S, Hoshino Y, Okumura M, Fujinaga T. 2006. Intracellular localization and concentration as well as photodynamic effects of benzoporphyrin derivative monoacid ring A in four types of rodent tumor cells. Cancer Lett 243:281-292.
35. Ost D. 2003. Photodynamic therapy in lung cancer. A review. Methods Mol Med 75:507-526.
36. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH. 2002. Mitochondrial bound type II of hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys Acta 1555:14-20.
37. Polo L, Valduga G, Jori G, Reddi E. 2002. Low-density lipoprotein receptors in the uptake of tumor photosensitizers by human and rat transformed fibroblasts. Int J Biochem Cell Biol 34: 10-23.
38. Rahimipour S, Ben-Aroya N, Ziv K, Chen A, Fridkin M, Koch Y. 2003. Receptor-mediated targeting of a photosensitizer by its conjugation to gonadotropin-releasing hormone analogues. J Med Chem 46:3965-3974.
39. Ricci E Jr, Marchetti JM. 2006. Zinc(II) phthalocyanine loaded PLGA nanoparticles lor photodynamic therapy use. Int J Pharmaceutics 310:187-195.
40. Roche JVE, Whitehurst C, Watt P, Moore JV, Krasner N. 1998. Photodynamic therapy (PDT) of gastrointestinal tumors: a new light delivery system. Laser Med Sci 13:137-142.
41. Roy I, Ohulchanskyy TY, Pudavar HE, Bergey EJ, Oseroff AR, Morgan J, Dougherty TJ, Prasad PN. 2003. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J Am Chem Soc 125:7860-7865.
42. Sadzuka Y, Tokutomi K, Iwasaki F, Sugiyama I, Hirano T, Konno H, Oku N, Sonobe T. 2006. The phototoxicity of photophrin was enhanced by PEGylated liposome in vitro. Cancer Lett 241: 42-48.
43. Yan F, Kopelman R. 2003. The embedding of meta-tetra(hydroxyphenyl) chlorine into silica nanoparticle platform for photodynamic therapy and their singlet oxygen production and pH-dependent optical properties. Photochem Photobiol 78: 587-591.
44. Vrouenraets MB, Visser GWM, Snow GB, van Dongen GAMS. 2003. Basic principles, applications in oncology and improved selectivity of photodynamic therapy. Anticancer Res 23:505-522.
45. Winkelman J. 1962. The distribution of tetraphenylporphine-sulfonate in the tumor-bearing rat. Cancer Res 22:589-596.
46. Winkelman JW, Collins GH. 1987. Neurotoxicity of tetraphenylporphinesulfonate TPPS4 and its relation to photodynamic therapy. Photochem Photobiol 46:801-807.